Atai Life Sciences Launches Bitcoin Treasury Strategy
- Atai Life Sciences plans to acquire $5 million worth of Bitcoin.
- The firm trades on the Nasdaq under the ticker ATAI.
- This move is aimed at mitigating inflation risks affecting cash reserves.
- The company filed an 8-K with the U.S. Securities and Exchange Commission.
- Founder Christian Angermayer cited valuation pressure as a key reason for this strategy.
Atai Life Sciences, a Nasdaq-listed biopharmaceutical company, announced plans to invest $5 million in Bitcoin to protect against inflation-related risks. The firm has filed necessary documentation with the SEC and aims to bolster its financial resilience through this strategy.
Source (2.6)https://decrypt.co/311014/another-publicly-traded-company-bitcoin-reserve?rand=52368
